Core Viewpoint - The global market for Polycythemia Vera (PV) drugs is expected to grow from $2 billion in 2020 to $2.9 billion by 2025, with a compound annual growth rate (CAGR) of 7.7% [5][6] Group 1: Overview of Polycythemia Vera (PV) - PV is a common subtype of myeloproliferative neoplasms characterized by increased red blood cell count, hemoglobin levels, or hematocrit, often accompanied by elevated white blood cells and platelets [2][3] - The disease primarily affects middle-aged and elderly patients, with a median age of onset around 65 years, and the global incidence rate is reported to be between 1.0 to 2.0 per 100,000 [3][4] Group 2: PV Drug Market Development - The PV drug market is concentrated, with the United States being the largest market, projected to reach $1.2 billion by 2025, accounting for 41% of the global market [5][6] - The Chinese PV drug market is expected to be $0.1 billion by 2025, influenced by a smaller patient base and reliance on inexpensive older drugs [6] Group 3: Approved PV Treatments - Hydroxyurea is the first-line cytoreductive therapy for PV, with nine products approved in China by the end of 2025 [6][7] - Pegylated interferon (PEG-IFN) is also used as a first-line treatment or for patients intolerant to or resistant to hydroxyurea, with the first long-acting interferon, ropeginterferon alfa-2b, approved in the EU in 2019 and in the US in 2021 [7][8] - Ruxolitinib, a JAK1/2 inhibitor, is indicated for patients intolerant to hydroxyurea, showing significant improvement in symptoms such as pruritus and early satiety [9] Group 4: Future Outlook for PV Treatment - The focus of PV treatment is shifting from merely preventing thrombosis to reducing the long-term treatment burden and potentially curing the disease [9] - Future research is needed to establish new treatment protocols based on clinical symptoms and molecular parameters, aiming for a transition from lifelong treatment to time-limited therapy [9]